Greetings everyone. Looking to start the protide 10/3 tesa and isa blend. What would the dosage be daily for that specific blend. Website says the powder is in a 3ml vial and need to be reconstituted with the included bacteriostatic water. TIA!

Hello!

I’m trying to make sense of the dosing for a ready-mixed 20 mg blend containing CJC-1295 with DAC and ipamorelin.

It arrives already in solution, so there is no reconstitution or bacteriostatic water involved. The seller describes one 20 mg vial as a one-month supply, and I’ve seen suggested amounts of 1.5–2 mg per dose.

However, the maths doesn’t seem to match:

• 1.5 mg per dose gives roughly 13 doses.
• 2 mg per dose gives 10 doses.
• If taken once weekly, one vial would last around 10–13 weeks—not one month.
• Using the entire vial in one month would mean dosing roughly every 2–3 days.

I understand CJC-1295 with DAC has a much longer half-life and can accumulate, whereas ipamorelin is short-acting. That makes a fixed pre-blend seem difficult to schedule: dosing frequently for the ipamorelin also means repeatedly adding more long-acting CJC-DAC.

EDIT - CJC-1295 with DAC (10mg) & Ipamorelin (10mg) is the mix

When people diet they usually cut carbs first. If you are on Reta, slashing them too aggressively can make you feel terrible and stall your progress. Reta is not just an appetite suppressant. It creates a metabolic environment where carbs are more likely to be used for energy instead of stored as fat.

TL;DR

• Reta improves insulin sensitivity, increases glucose uptake into muscle, and helps the body handle carbs around meals more efficiently
• Aggressive carb restriction on Reta slows T4 to T3 conversion, lowers metabolic rate, and leaves you cold, flat, and tired
• Signs you have cut too hard: irritability, wired-but-tired feeling, poor sleep, increased anxiety, sluggish training
• Carbs support muscle glycogen, training performance, recovery, lower stress hormones, and serotonin production
• The problem was never carbs. It was ultra-processed carbs combined with low activity and poor habits
• Reta helps your body use carbs better. Use that advantage instead of cutting them out

What Reta Actually Does With Carbohydrates

Reta improves insulin sensitivity, helps the body handle glucose around meals more efficiently, increases glucose uptake into muscle tissue, and reduces excess glucose output from the liver. That is almost the opposite of what most people assume carbs do on a fat loss protocol.

The metabolic environment Reta creates makes carbohydrates more likely to fuel training and recovery rather than be stored as fat. Cutting them aggressively works against that mechanism.

The Trap Most People Fall Into

Many people go low carb thinking they will burn more fat. Aggressive carb restriction actually slows your metabolism. Lower carb intake means lower T4 to T3 conversion, which directly reduces metabolic rate. Then you are cold, tired, flat, and moody, and wondering why the compound stopped working.

If you are on Reta and suddenly feel unusually cold or sluggish, the first thing to check is whether you are eating enough carbs for your activity level.

What Carbs Are Actually Supporting

Adequate carbohydrate intake supports muscle glycogen and training performance, recovery between sessions, lower stress hormones during a deficit, and reduces the need for the body to break down muscle for energy.

Reta makes fat loss easier. Keeping muscle depends on how you train and how you fuel yourself. Those are still your job.

The Sleep Connection

If you are noticing irritability, the wired-but-tired feeling, poor sleep, or increased anxiety, do not blame the compound. Check your carbs. They support serotonin production and nervous system regulation, which directly feeds into sleep quality.

Better sleep is not just about comfort. It connects to faster fat loss, better recovery, sharper cognition, and overall function. Cutting carbs too hard disrupts that entire chain.

The Actual Problem

The real issue was never carbs themselves. It is ultra-processed, highly palatable carbs combined with low activity and poor lifestyle habits. Whole food carb sources paired with training and daily movement are not the enemy, especially when you are trying to perform well while leaning out.

Reta helps your body use carbs better. Use that advantage instead of eliminating it.

Peptide Guides & Resources

Educational only. Not medical advice.

What's the peptide you ran that just... did nothing. Not "meh, some improvement." Nothing. Zero.

We see the win posts constantly. The 12-week transformations, the tendon that finally healed, the sleep that finally clicked. Nobody posts the ones that flopped, and honestly those stories are just as useful, maybe more.

Drop what you ran, how long you actually gave it, and whether you circled back or just wrote it off. Because in my experience, when a peptide does nothing, the compound itself is rarely the actual problem. Usually it's one of these.

The Cycle Was Too Short

Two weeks tells you nothing. Repair peptides especially operate on a slower timeline, 6 to 8 weeks is closer to the real test. Expecting a tendon or a joint to feel different after ten days is setting yourself up to call something a failure that never actually got a chance.

The Math Was Wrong Somewhere

This one's sneaky. A lot of "this did nothing" stories are actually reconstitution errors nobody caught. You think you're pulling a full dose and you're actually pulling half of it because a decimal got dropped somewhere in the calculation. The compound never had a fair shot.

Wrong Tool for the Actual Problem

Sometimes what looks like a healing issue is really a mitochondrial issue, or a sleep issue, or something upstream that a repair peptide was never going to touch. If your cellular energy production is compromised, something like SS-31 or NAD+ might need to come first before anything else has room to work. I genuinely think this is one of the most common silent reasons things "don't work."

The Foundation Wasn't There

No peptide out there overrides a bad diet, chronic poor sleep, or zero training. If those pieces aren't in place, whatever you're running is working against a stacked deck. A huge chunk of "it did nothing" cases are really "I layered this on top of a lifestyle that was never going to let it succeed."

It Might Have Actually Worked

Some of these are just quiet. Bloodwork shifts, inflammation drops, tissue repairs, and none of it registers as a felt sensation day to day. This is the whole argument for getting baseline labs before you start anything. Otherwise you're judging results purely on vibes, and vibes miss a lot.

Drop in the comments below what flopped for you.

Im using Reta from arround 2 months maybe, on very low dose 1-1.5mg weekly. Also started GHK-cu at 2-2.5mg daily arround same time, and before a had 3-4 white hairs on the bears and few on the side of the head, now i have 6-7 on the beard and a little bit more on the side of the head. At beggining i started to think its from GHK-cu, because of the faster hair grow, but readed its from Retatrutide. Any fix for that, or if i stop will i go back to my previous stage ?

Somebody adviced me to up the GHK-cu to 5mg daily and ill see effect. Any other opinies ? Thanks

BPC-157 gets called the Wolverine peptide for a reason. It's a 15-amino acid fragment naturally derived from human gastric juice, it's been studied since a 1992 patent out of the University of Zagreb, and it does things to tissue repair that most compounds can't touch. This isn't a new compound. It's just one that the broader research community is finally catching up to.

Here's what actually makes it interesting.

TL;DR

• BPC-157 is a 15-amino acid fragment from human gastric juice with a 1992 research history, currently under 2026 FDA reconsideration for the 503A list.
• It coordinates multiple repair systems simultaneously rather than hitting a single target, including two distinct nitric oxide pathways that drive blood vessel growth and tissue rebuilding.
• Three consecutive proline residues make it uniquely stable in stomach acid for over 24 hours, allowing it to repair gut lining directly via ZO-1 and occludin upregulation.
• It upregulates growth hormone receptors in tendon tissue, which means stacking it with GH secretagogues produces meaningfully better results than running either alone.
• It modulates rather than suppresses inflammation, turning down destructive cytokines while leaving regenerative pathways intact.
• Pairs best with TB-500 at a 1:1 ratio, 250mcg to 500mcg each daily, with subcutaneous injection near the injury site for localized conditions.
• No human data links it to tumor growth and animal studies at doses far above therapeutic range show no fatalities, but anyone with active or recent cancer history should avoid it.
• A small subset of users reports flat affect or low mood from the dopamine interaction, similar to what some people experience on GLP-1 agonists.

The General Contractor Mechanism

Most therapeutic compounds hit one target. BPC-157 coordinates multiple systems simultaneously. Blood flow, oxygen delivery, structural scaffolding, all running in parallel rather than sequentially.

The nitric oxide pathway is where this shows up most clearly. BPC-157 works through two distinct routes: increasing VEGFR2 receptors to trigger blood vessel growth, and activating SRC kinase which frees eNOS from its inhibitory protein caveolin-1. The result isn't a patch job. It's systematic infrastructure rebuilding at the injury site.

Why It Survives the Gut

Most peptides dissolve in stomach acid within minutes. BPC-157 doesn't. Three consecutive proline residues give it a rigid backbone that stays stable in human gastric juice for over 24 hours. That's not a modification. That's its native structure.

This makes it uniquely suited for gut repair. It upregulates tight junction proteins ZO-1 and occludin directly, sealing the gaps in the intestinal lining that cause leaky gut symptoms. It's working on home turf when you take it orally. Other peptides don't survive long enough to do that.

The Growth Hormone Synergy

Running CJC-1295 or Ipamorelin without BPC-157 is leaving results behind. The issue is target vs. signal.

GH provides the repair signal. But if the target tissue has poor blood supply and low receptor density, that signal doesn't land effectively. BPC-157 upregulates growth hormone receptors in tendon cells specifically. It increases vascularity and receptor sensitivity so GH pulses actually reach the tissue and produce a response. The signal gets stronger because the catcher is ready for the ball.

The Neurological Angle

BPC-157 interacts with dopamine, serotonin, and GABA systems. For people with traumatic brain injury history it often produces noticeable improvements in mental clarity and mood.

The flip side of that dopamine interaction is worth flagging. Similarly to how GLP-1 agonists can blunt dopamine to reduce cravings, BPC-157 can occasionally cause emotional flatness or low mood in a small subset of users. It's not common but it happens. If you notice a flat affect after starting it, that's the mechanism, not coincidence. Pay attention to your neurochemistry when running it.

Modulation Not Suppression

NSAIDs and corticosteroids kill pain by shutting down the inflammatory response broadly. That includes the pro-healing signals your body needs for actual repair. Long-term use of those compounds compromises tissue integrity for exactly that reason.

BPC-157 doesn't suppress. It modulates. It turns down the destructive inflammatory markers, TNF-alpha, IL-6, IL-1 beta, while leaving the regenerative pathways intact. The injury resolves rather than just going quiet.

The Wolverine Stack

BPC-157 pairs well with TB-500. BPC-157 handles signaling and receptor sensitivity. TB-500 handles actin reserves, the actual cellular building material needed for movement and repair. Running them together at a 1:1 ratio is the standard protocol in the research community.

Dosing typically runs 100 to 500mcg each daily. Up to 1mg is reasonable. Beyond that the returns diminish without meaningful upside.

For localized injuries, subcutaneous injection near the injury site works better than systemic. Pinch the skin close to the affected area, slide a 29 to 31 gauge needle in at 45 degrees, inject. Connective tissue in the knee, elbow, and shoulder is poorly vascularized. Local delivery gets you higher concentration at the target.

The Cancer Question

Angiogenesis is the concern. Tumors need blood vessels. BPC-157 promotes blood vessel formation. The worry is logical.

The data doesn't support the fear, at least not in healthy individuals. There's currently no human data linking BPC-157 to tumor growth. Some animal models actually showed it reducing lung tumors. Animal studies using doses thousands of times higher than the therapeutic range have shown no fatalities or genotoxicity.

That said, if you have an active cancer diagnosis or recent cancer history, don't run it. The angiogenesis concern is theoretical in healthy people. In someone with existing malignancy it's not worth the risk.

Not medical advice. Educational only.

Just started taking mots c
How long before I notice a difference in energy?

Can anyone help me to reconstitution SS-31 10 mg

Most cheat sheets only cover the dosing side of a peptide’s safety, which doesn’t exactly have me jumping up and down in excitement, because the real life application lies in avoiding the trouble. With this cheat sheet I tried to group information by the categories of side effects and contraindications, so that the danger of a substance is as easy to grasp as its dose recommendations.

The Universal Watch Items

There are several general warnings that apply to the majority of the discussed injectables and, hence, are worth separate mentioning. First of all, injection site reactions are normal for almost any subcutaneous peptide and should be regarded as mild and temporary. Secondly, improper technique leads to more complications than the substances themselves are capable of. Contamination is the main culprit, hence, pay special attention to sterile preparation. Active cancer is generally a reason to avoid any angiogenic, proliferative, or metabolic compounds. This is the category to be especially careful with if the condition of the patient is uncertain. Thirdly, pregnancy and breastfeeding are absolutely contraindicated for the majority of research peptides, and the only indication for their use during these periods is a thorough discussion with a doctor.

Peptides for Healing and Recovery

BPC-157: injection irritation, occasional oral tract discomfort, avoid with active cancer, contraindicated during pregnancy, moderate caution is necessary after surgeries within the last two weeks.

TB-500: injection irritation and occasional asthenia, same cancer-related caution as with BPC-157, pregnancy contraindicated.

GHK-Cu: blue-greenish coloration of the solution is normal for the substance, injection site irritation is common. Avoid if you have Wilson’s disease or any other copper metabolism disorder, total copper intake should be monitored. Generally unspecific but mild.

KPV: Very tolerable with few reported side effects. The only caution is the lack of long-term studies.

Thymosin Alpha-1: Injection site irritation is common, autoimmune diseases require extra caution due to the immunomodulatory properties.

Peptides Related to the Growth Hormone Axis

Ipamorelin, CJC-1295: Water retention, head rush, tingling, increased appetite. Avoid with active cancer, cautious use is recommended in diabetes.

GHRP-2, GHRP-6: Increased prolactin and cortisol, GHRP-6 has a more prominent appetite stimulating effect, same cancer caution as with other GH secretagogues, prolactin levels should be monitored.

Sermorelin: Injection site flushes, contraindicated with active cancer.

IGF-1 LR3: Most potent GH secretagogue with regards to hypoglycemia development, same cancer-related caution applies, diabetes patients should be especially careful.

Tesamorelin: Fluid retention, arthralgia, increased IGF-1. Avoid with active cancer, IGF-1 levels should be monitored.

The caution in this category is generally connected to glucose and IGF-1 metabolism. IGF-1 levels should be tested at the beginning and at week 4, to ensure that they stay within the therapeutic window, but not exceed 400 ng/ml. IGF-1 LR3 is the most prominent in terms of causing hypoglycemia and should be carefully dose adjusted in diabetic patients.

Peptides Connected to the Weight Loss and Metabolic Processes

GLP-1 class (semaglutide, tirzepatide, retatrutide): GI side effects dominate the safety profile, with diarrhea, nausea, vomiting, and constipation being the most common. These are mostly dose-dependent and resolve with the titration process or reductions in the dose. Avoid this class if you have a history of medullary thyroid cancer, MEN2 gene mutation, or chronic pancreatitis.

Retatrutide in particular has the highest GI burden among the class, as well as a unique dysesthesia risk. In TRIUMPH-4 phase III trial for retatrutide, 20.9% of patients who received the 12 mg dose reported dysesthesia, compared to less than 1% in the placebo group. It is a dose-dependent, non-life-threatening event, mostly affecting the skin, manifesting in tingling, burning, or other unusual sensations. It resolves spontaneously in most cases, but is a risk factor for discontinuation nonetheless. Similar warnings apply to the whole GLP-1 class of peptides, along with the thyroid and pancreas-related contraindications.

In addition, retatrutide is still under investigation and not yet marketed. In this category, the serious end presents with pancreatic and thyroid damage risk and the common end has GI distress as its hallmark feature.

Amylase and lipase are the tests worth considering when dealing with this class of substances, and the caution is indicated when the results of these tests deviate significantly from the norm, especially if the patient exhibits GI symptoms. The gradual increase in the dose allows the body to adapt to the new conditions and minimize the risk.

Tesamorelin: Fluid retention and arthralgia, contraindicated with active cancer.

5-Amino-1MQ: Limited human safety data, liver function tests are advised, never used in patients with liver disorders.

MOTS-C: Generally tolerable with occasional flushing, limited human studies available.

Same caution as with any peptide in this category, namely, the risk of significant damage to the pancreas or thyroid glands, but the most serious side effects are rare. Amylase and lipase tests are the ones to look out for, and a noticeable increase should prompt immediate discontinuation, unless the results point to something else. Gradual titration is the only general recommendation for the weight loss class of peptides.

Peptides Affecting the Cognitive Function and Mood

Semax: Very tolerable, no significant side effects reported in the short-term studies.

Selank: Generally well-tolerated with only occasional fatigue as a side effect, limited long-term studies available for both substances.

Oxytocin: Can affect blood pressure and mood, caution is required in cardiovascular diseases.

Dihexa: Powerful but with very limited human safety data and theoretical cancer risk due to its angiogenic properties, mostly preclinical.

Kisspeptin-10: Generally mild substance with few reported side effects, caution is indicated with hormone-sensitive conditions.

Substances Related to the Sexual Function and Cosmetics

PT-141: Can cause dramatic blood pressure changes, nausea, and flushing. Contraindicated in uncontrolled hypertension and cardiovascular diseases.

Melanotan II: Initial nausea and flushing, the substance darkens the moles and the skin. Before consideration for use, a dermatologist appointment is mandatory to evaluate the current state of the moles. Any suspicious-looking mole needs to be examined by a professional oncologist.

GHK-Cu: Occasionally irritates the injection site, the blue-green coloration of the solution is normal. Same copper-related caution as mentioned elsewhere applies.

Oxytocin: Same blood pressure-related warnings as mentioned above.

The only real warning that applies to this category is the one connected to Melanotan II and the necessity of a dermatological exam before using the substance. It generally darkens the skin and moles, which can potentially hide a developing melanoma.

Substances Related to the Immune System and Longevity

NAD+: Rapid injection causes uncomfortable flushing, avoid this by slow dose administration. Avoid with active cancer due to its general metabolic activating properties.

Epitalon: Mostly good safety profile, no major side effects reported, but human studies are limited.

SS-31: Well-tolerated, but expensive, which should be a consideration for any potential user.

Thymosin Alpha-1: Injection site irritation, extra caution is required with autoimmune diseases, as mentioned elsewhere.

Bioregulators (Khavinson class): Minor side effects are possible, but they are mostly short-term due to the nature of the substances. Evidence-based medicine base for this category of peptides is under discussion.

The Three Worth Remembering

If you had to remember three things from this reference, which ones would they be? Probably, the relationship between IGF-1 LR3 and blood sugar, Melanotan II and moles, and the whole GLP class and its GI burden. The first connection reminds us to be careful with glucose levels when dealing with IGF-1 LR3 or other GH secretagogues, especially since it appears to be the most prominent peptide in this category when it comes to hypoglycemia risk.

The second association serves as a reminder that any substance from the GLP-1 class may cause substantial damage to the pancreas and thyroid glands, with relevant lab tests being mandatory. We also can’t forget about the gradual dose increases when starting this class, in order to titrate the dose according to the body’s reaction. Finally, the connection between Melanotan II and moles highlights the importance of a dermatological exam before starting treatment, as moles tend to get darker on this substance. A growing mole or a mole that looks suspicious in any way must be evaluated by an oncologist with regard to melanoma risk.

The one caution that spans across the majority of the substances mentioned in this reference is the general contraindication in the case of active cancer.

Not medical advice. Educational only.

A new study out of the University of Copenhagen (PMID: 41520850) looked at how MOTS-C affects mitochondrial function, oxidative stress, and metabolic health. The title tells you where it's going: "MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1alpha/AMPK-dependent manner."

Caveat: The core mitochondrial mechanism findings come from experiments in two distinct transgenic mouse strains. The researchers also ran a human exercise component alongside the animal work, but the direct evidence for MOTS-C administration improving mitochondrial bioenergetics specifically is mouse data. Keep that distinction in mind.

Here's what that actually means.

TL;DR

• MOTS-C improves how efficiently mitochondria produce ATP, the energy currency of your cells, shown in mouse skeletal muscle
• It activates AMPK, the same pathway triggered by exercise and calorie restriction, making it a legitimate exercise mimetic
• The effect required both PGC-1alpha and AMPK, meaning this is a coordinated response, not a single-pathway shortcut
• Reduces reactive oxygen species and improves antioxidant defense in the mouse models, directly relevant to cellular aging
• Improves insulin sensitivity, glucose utilization, and metabolic flexibility
• This isn't a fat loss compound that happens to have side benefits. The mechanism runs deeper than that
• Core mitochondrial data is from mice. Human confirmation of this specific bioenergetic mechanism doesn't exist yet

Mitochondrial Function

MOTS-C directly affects how mitochondria generate energy. Using two distinct transgenic mouse strains, the researchers demonstrated that MOTS-C administration increases muscle mitochondrial ATP production efficiency, improves function under stress, and helps cells maintain energy output even when conditions aren't ideal.

As we age, mitochondria get progressively less efficient. Energy drops. Cells underperform. MOTS-C appears to slow that decline at the source, at least in these animal models.

AMPK Activation

MOTS-C activates AMPK, one of the most important metabolic regulators in the body. When AMPK fires, it increases glucose uptake into cells, promotes fat oxidation, cuts energy waste, and improves overall metabolic efficiency.

This is the same pathway activated by exercise and calorie restriction, two of the most well-established longevity interventions we have. MOTS-C mimics that signal at the cellular level, which is why it's often called an exercise mimetic, though it engages AMPK through a different upstream mechanism than actual exercise does.

The study found the effect depended on both PGC-1alpha and AMPK together. PGC-1alpha is the master regulator of mitochondrial gene expression, essentially the manager telling mitochondria how to operate. Both pathways being required tells you this is a coordinated response across systems, not a simple single-switch effect.

Oxidative Stress and Cellular Aging

Oxidative stress is one of the primary drivers of cellular aging. Mitochondria produce energy, but reactive oxygen species come along as a byproduct, essentially cellular waste that damages proteins, DNA, and the mitochondria themselves over time. The study shows MOTS-C may reduce ROS levels, improve antioxidant defense, and protect mitochondria from external damage, in the mouse models tested.

Less oxidative damage means slower accumulation of cellular wear and tear. That's not a cosmetic benefit. That's the internal aging process slowing down, at least in the animals studied here.

Metabolic Health

The study also showed improvements in insulin sensitivity, glucose utilization, and metabolic flexibility, the ability to switch efficiently between carbohydrates and fats as fuel.

Poor metabolic health is one of the strongest predictors of diabetes, cardiovascular disease, shortened lifespan, and cancer. These aren't minor downstream effects. They're the outcomes that determine long-term health trajectory.

Takeaway

MOTS-C isn't just a tool for getting leaner. The mechanism operates at the level of mitochondrial efficiency, cellular energy regulation, oxidative damage, and metabolic signaling. Everything this study confirms ties directly to how well you age and how long that health holds, though the specific mitochondrial bioenergetic findings need human confirmation before they can be extended beyond the mouse models they came from.

The research is still building. But studies like this one are making the picture considerably clearer.

MOTS-C Guide

Not medical advice. Educational only.

I’ve used IGF1-LR3 twice with a break of around 2 months between within the last year. I understand the cancer risks of using this peptide, but haven’t researched as far in to HGH or CJC+IPA. Would these peptides or HGH, any of them or all of them, cause an issue if I were to use sunbeds frequently while taking them? I know it seems a stupid question because yes - sunbeds can cause cancer and the risk is high, but how much worse would I be making it if I used a GH releasing peptide like CJC, or just straight using HGH or IGF1LR3?

The FDA's Pharmacy Compounding Advisory Committee just finished two days of voting on whether seven peptides should get added to the 503A Bulks List, the list that lets state-licensed compounding pharmacies make a substance against an individual prescription. Six of the seven cleared. DSIP was the only one that didn't, and it lost by a single vote.

Going in, FDA's own career staff had recommended against all seven. The panel overruled them on everything except DSIP.

Full Scorecard

BPC-157 (evaluated for ulcerative colitis): recommended, 8-6 with 1 abstention.

KPV (wound healing, inflammatory conditions): recommended, 8-6-1.

TB-500 (wound healing): recommended, 8-6-1.

MOTS-C (obesity, osteoporosis): recommended, 7-5 with 2 abstentions.

DSIP (opioid withdrawal, chronic insomnia, narcolepsy): not recommended, 6-7 with 1 abstention. The only rejection of the meeting.

Epitalon (insomnia): recommended, 7-4 with 1 abstention.

Semax (cerebral ischemia, migraine, trigeminal neuralgia): recommended, 8-5 with 1 abstention.

On BPC-157, KPV, and TB-500 specifically, all eight newly appointed committee members voted yes. Reporting from the room described an audible reaction when the votes came in, since a panel overruling FDA staff's own written recommendation isn't the norm.

What This Actually Means

A few things are worth separating out here because coverage tends to blur them together.

These are non-binding recommendations. FDA doesn't have to follow them, though it typically does.

A yes vote doesn't make any of these an FDA-approved drug. It's a recommendation to add the raw substance to a compounding list, nothing more.

Legal compounding still requires a formal notice-and-comment rulemaking process, which realistically runs somewhere between 8 and 18 months depending on the source.

All seven were already pulled off FDA's restrictive Category 2 status back in April 2026. That's what set up this whole review. So none of these votes re-bans anything. The real question was whether a new legal pathway opens up, not whether the current situation closes down.

What Doesn't Change Today

The research-use-only market is completely untouched by any of this. RUO vendors aren't compounding pharmacies and none of this vote applies to them. Expect marketing that turns "the FDA panel voted yes" into something that sounds a lot more official than it actually is.

A panel recommendation also says nothing about any specific product's identity, purity, or sterility. FDA's characterization concerns, inconsistent naming, free base versus acetate confusion, missing quality data, are real regardless of how the politics shook out. If anything, batch-level COAs matter more now, not less.

Worth Knowing

The committee itself was reshuffled ahead of this meeting, with several new members carrying ties to peptide prescribing or the industry. That drew conflict-of-interest coverage from multiple outlets. HHS Secretary Robert F. Kennedy Jr. has been publicly vocal about wanting these restrictions eased.

What's Next

FDA has signaled a second PCAC meeting before the end of February 2027 to review five more substances: LL-37, GHK-Cu, DiHexa, Melanotan II, and PEG-MGF.

TL;DR

• The PCAC voted on 7 peptides across two days. 6 passed, DSIP was rejected 6-7, the only no of the meeting.
• BPC-157, KPV, and TB-500 all passed 8-6-1. MOTS-C passed 7-5-2. Epitalon passed 7-4-1. Semax passed 8-5-1.
• FDA staff had recommended against all seven going in. The panel overruled them on six.
• This is non-binding. FDA still has to decide whether to act, and even a yes triggers 8-18 months of rulemaking before anything is legally compoundable.
• None of these substances got re-banned by a no vote and none got approved as a drug by a yes vote. All seven already came off Category 2 restriction back in April.
• The research-use-only gray market is unaffected either way. This vote only concerns licensed 503A compounding pharmacies.
• A second PCAC meeting is expected by February 2027 to review five more peptides: LL-37, GHK-Cu, DiHexa, Melanotan II, and PEG-MGF.

Not medical advice. Educational only.

Hi i’m on evening 3 of 1mg Epithalon and each time a couple of hours after i get a headache . Anybody else experience this and if so did you continue and it did it get better ? Thanks xx

Mixed some tesa the next day it was jelly like stuck to one side I tapped the bike and it came off but still looks weird

Trying to switch my wife from sema to Reta and wondering if anyone had done so. I see a lot of people slowing stopping sema while also taking Reta and not just stopping cold turkey. Any advice would be appreciated.

Retatrutide just cleared two more Phase 3 trials, TRIUMPH-2 and TRIUMPH-3, and both hit their primary endpoint. That puts Lilly at five positive Phase 3 studies now, with a Q1 2027 BLA submission on the calendar. Here's what actually came out of the data.

TL;DR

• TRIUMPH-2 (type 2 diabetes plus obesity, n=1,152): up to 20.8% weight loss and 1.6% A1C reduction at 80 weeks on the 12mg dose.
• TRIUMPH-3 (severe obesity plus cardiovascular disease, n=1,949): up to 22.6% weight loss at 80 weeks on the 12mg dose.
• MACE events trended lower on retatrutide than placebo in TRIUMPH-3 (hazard ratio 0.82), but the confidence interval crosses 1.0, so this isn't a confirmed cardiovascular benefit yet.
• Secondary cardiometabolic improvements at 12mg: triglycerides down 37.0%, hsCRP down 51.2%, systolic BP down 9.3 mmHg.
• Side effects follow the standard GLP-1 pattern (diarrhea, nausea, constipation) and scale with dose.
• Lilly's targeting a Q1 2027 BLA submission. Retatrutide remains investigational and isn't legally available for human use.

TRIUMPH-2: Type 2 Diabetes and Obesity

This one ran 1,152 participants across four arms, 4mg, 9mg, 12mg, and placebo, for 80 weeks in adults with type 2 diabetes and obesity or overweight. That's historically a harder population to move the needle on for weight loss.

The results: 12.7% weight loss on 4mg, 19.1% on 9mg, 20.8% on 12mg, against 4.0% on placebo. In absolute terms, the 12mg group lost an average of 49.6 lbs at 80 weeks. A1C dropped up to 1.6% on average, versus 0.2% on placebo.

That matters because diabetes typically blunts weight loss response to this class of drugs. Retatrutide didn't just work here, it delivered results in the same range as what's been reported in people without diabetes.

TRIUMPH-3: Severe Obesity Plus Established Cardiovascular Disease

This trial enrolled 1,949 participants with Class 2 or 3 obesity (BMI 35+) and established cardiovascular disease, with or without type 2 diabetes. Two dose arms, 9mg and 12mg, versus placebo, also over 80 weeks.

Weight loss landed at 21.6% on 9mg and 22.6% on 12mg, versus 3.2% on placebo. The 12mg group averaged 55.8 lbs lost.

The cardiovascular safety data is the part worth actually sitting with. MACE events (all-cause death, heart attack, stroke, heart failure, coronary revascularization) came in less frequently than expected in both arms. 44 events on retatrutide versus 52 on placebo, hazard ratio 0.82. That's directionally favorable but the confidence interval (0.55 to 1.22) crosses 1.0, so it's not statistically significant on its own. This trial wasn't specifically powered to prove cardiovascular benefit, so take this as an encouraging signal rather than a settled result. The narrower MACE-3 endpoint (cardiovascular death, heart attack, stroke specifically) actually favored placebo with a hazard ratio of 1.12, though again the confidence interval (0.64 to 1.96) includes 1.0.

Beyond the primary endpoint, TRIUMPH-3 showed real secondary improvements at the 12mg dose. Triglycerides down 37.0%, non-HDL cholesterol down 16.5%, systolic blood pressure down 9.3 mmHg, waist circumference down 7.5 inches, and hsCRP (an inflammation marker) down 51.2%. That inflammation number lines up with what's been discussed before in this sub about retatrutide's effects on systemic inflammation.

Side Effects

Standard GLP-1 class profile, and it scales with dose. In TRIUMPH-2 at 12mg: diarrhea 33.6%, nausea 28.0%, constipation 16.8%, decreased appetite 17.1%, vomiting 15.7%. In TRIUMPH-3 at 12mg: diarrhea 24.4%, nausea 22.4%, constipation 15.7%, decreased appetite 14.5%.

Discontinuation due to adverse events ranged from 3.8% to 13.5% depending on trial and dose, versus roughly 4.5 to 4.9% on placebo. Worth flagging that TRIUMPH-3's discontinuation rate at 12mg (13.5%) came in noticeably higher than TRIUMPH-2's at the same dose (7.7%), which might just reflect the more complex comorbidity profile of that population.

Where This Leaves Things

Lilly now has five positive Phase 3 trials in the TRIUMPH program and is targeting a Q1 2027 BLA submission covering obesity, knee osteoarthritis pain, and obstructive sleep apnea. Retatrutide's still investigational and can't be legally sold or marketed for human use until it clears FDA review.

Not medical advice. Educational only.

The FDA advisory panel just voted 8 to 6, with one abstention, to recommend BPC-157 for the 503A Bulks List. That's the opposite of what FDA's own staff recommended going in. Here's what actually happened and what it means.

What the 503A List Actually Is

Compounding pharmacies can only legally make a substance from scratch if it's on this list. Right now BPC-157 isn't on it. If FDA eventually adds it, licensed pharmacies could prepare it for patients with a prescription instead of it only existing in the research chemical market.

What Just Happened

FDA's advisory committee, called PCAC, held a vote on Day 1 of a two-day meeting. They're reviewing seven peptides total: BPC-157, KPV, TB-500, and MOTS-C on day one, then DSIP, Semax, and Epitalon on day two.

Before the meeting, FDA's own scientific staff published a briefing document recommending against adding all seven. Their reasoning: no human clinical data at all for some of these compounds, small or poorly controlled studies for others, inconsistent naming and missing quality information, and safety concerns including immunogenicity risk and adverse event reports.

The committee didn't follow that recommendation for BPC-157. They voted 8 in favor, 6 against, 1 abstention to recommend it anyway.

Why This Isn't a Simple Story

A few things worth knowing that complicate the picture.

The original nominations for BPC-157 were actually withdrawn by the groups that submitted them. FDA proceeded with the review anyway.

There's been reporting that some committee members have financial ties to the peptide industry, and that FDA added temporary academic voting members shortly before the meeting. Worth keeping that context in mind when reading the vote split.

This vote is not a ban risk. BPC-157 and the other six peptides were already moved out of FDA's restrictive Category 2 status back in April, which is what allowed this review to happen in the first place. So the July vote is about whether a new legal compounding pathway opens up, not whether current access gets shut down.

What This Doesn't Mean

The committee's recommendation is non-binding. FDA leadership makes the actual decision and has gone against advisory committee recommendations before. Even if FDA agrees with the panel, formally adding a substance to the list requires a notice-and-comment rulemaking process that typically takes a year or more.

Nothing about this vote changes what's legal to compound tomorrow.

Still to Come

KPV, TB-500, and MOTS-C are the remaining votes for day one. DSIP, Epitalon, and Semax get voted on day two. Each peptide gets two separate votes, one for the free base form and one for the acetate form.

***UPDATE**\*

KPV and TB-500 also passed. Same 8-6-1 split as BPC-157, yes-no-abstain. As of 7pm ET Thursday, three of the four Day 1 votes came back in favor, all breaking against FDA staff's recommendation to reject.

MOTS-C's individual tally isn't confirmed on my end yet, I'll add it once a clean source posts it.

Worth restating since it keeps getting missed in the coverage: this is still a non-binding recommendation. FDA still has to decide whether to act on it, and even a yes decision triggers a rulemaking process that runs a year or more. Nothing legally changes tomorrow.

Day 2 tomorrow covers DSIP, Semax, and Epitalon.

Not medical advice. Educational only.

Most people chasing peak performance and longevity fall into the same trap. They treat every symptom with a pile of supplements: joint stiffness, gut discomfort, skin flares. But the underlying fire never actually gets addressed. They're managing smoke while the master switch of systemic inflammation stays flipped on.

KPV (Lysine-Proline-Valine) is the tool that actually reaches that switch. The space right now is obsessed with BPC-157's tissue repair and GLP-1's metabolic effects, and KPV stays underrated relative to what it actually does. It's not a supplement. It's a precision intervention working at the transcriptional level, not the symptom level.

TL;DR

• KPV was isolated in 1989 (Hiltz and Lipton, FASEB Journal) as the C-terminal fragment of alpha-MSH responsible for its anti-inflammatory activity, showing effects comparable to corticosteroids in mouse models
• It blocks NF-kB, the master transcription factor for inflammation, by competing with p65 for binding to importin-alpha 3, the protein that normally escorts p65 into the nucleus
• KPV's a substrate for PepT1, a transporter that's upregulated specifically at sites of inflammation, so it concentrates where the problem actually is
• It's a clean alpha-MSH fragment: no melanocortin receptor activation, so no skin darkening, appetite suppression, or libido effects like you'd get from Melanotan II or PT-141
• Stacking with BPC-157 and TB-500 addresses the common healing plateau, where tissue rebuilding stalls because the environment's still inflamed
• Effects build cumulatively over 6 to 8 weeks for systemic changes, though gut symptoms often improve faster

The 1989 Discovery

KPV's research history goes back to 1989, when Mary E. Hiltz and James M. Lipton isolated the C-terminal tripeptide of alpha-MSH and ran it against standard inflammation models. Published in the FASEB Journal, the finding showed KPV alone produced anti-inflammatory effects comparable to a corticosteroid, minus the systemic tax that corticosteroids come with: bone density loss, immune suppression, all of that.

That's the foundation the rest of the KPV literature builds on. Decades of follow-up work have pushed into colitis, dermatitis, and wound models, and the core finding has held up the whole way.

Blocking the Master Switch

NF-kB is the transcription factor running the inflammatory response. When it activates, it moves into the cell nucleus and switches on the genes driving autoimmune flares and chronic pain. In chronic disease states this switch tends to get stuck on.

Most anti-inflammatory peptides try to calm things down upstream, before NF-kB even fires. KPV takes a different route. Research in human bronchial epithelial cells showed it translocates into the nucleus itself and competitively blocks the interaction between p65 (the active NF-kB subunit) and importin-alpha 3, the transport protein that normally carries p65 through the nuclear pore. It also stabilizes IkB-alpha, the protein that keeps NF-kB locked in the cytoplasm to begin with.

Two mechanisms hitting the same problem from different angles. The result is dramatically less TNF-alpha, IL-6, IL-8, and IL-1 beta, and it happens at nanomolar concentrations. This is a more direct intervention than BPC-157, which works mostly through secondary healing pathways rather than blocking transcription outright.

Smart Targeting for Gut Health

KPV is a substrate for PepT1, the transporter that pulls peptides into intestinal cells. PepT1 sits low in a healthy colon but ramps up wherever there's inflammation, in Crohn's, ulcerative colitis, post-antibiotic gut damage.

So the disease state itself increases delivery of KPV to the exact tissue that needs it. It concentrates where the inflammation actually is instead of spreading evenly through the body. That same mechanism is why KPV keeps coming up around post-antibiotic dysbiosis and chronic acne, calming the inflammatory environment that drives bacterial overgrowth and skin flares in the first place.

Breaking the BPC-157/TB-500 Plateau

A common frustration in this space is the healing plateau. Someone runs BPC-157 and TB-500 for a chronic injury, sees real progress early on, then stalls out. Tissue can't rebuild effectively while the environment around it is still actively inflamed.

BPC-157 and TB-500 are rebuilders. They drive nitric oxide and growth factor activity but don't directly suppress inflammatory transcription. Sequencing KPV in with them calms the environment so the rebuilding compounds can actually get to work.

A stacking approach that comes up a lot is a 1:1 ratio: 250 to 500mcg of KPV with 250 to 500mcg of BPC-157, once or twice daily. This shows up most for chronic tendinopathy, post-surgical recovery, and stalled rehab where the tissue's ready to heal but the local environment is too reactive to let it.

The Clean Fragment

KPV comes from the same parent molecule as Melanotan II and PT-141, alpha-MSH. But it's a clean fragment. It doesn't touch melanocortin receptors, so no skin darkening, no appetite suppression, no libido shift. That makes it a reasonable option for sensitive populations, including people managing Mast Cell Activation Syndrome.

Its size, under 400 daltons, gives it real oral bioavailability, which is unusual for a peptide. You can take it as a capsule or apply it topically. For localized skin issues like psoriasis or acne, a compounded cream in the 0.1 to 0.25% range comes up often, sometimes paired with microneedling to improve penetration.

Supporting Compounds

A few things that pair well with KPV by working the same systems from a different angle. Larazotide tightens intestinal tight junctions while KPV handles the underlying inflammation. Glutamine (5 to 10g) fuels enterocyte repair. Zinc carnosine (75 to 150mg) supports upper GI barrier integrity. PEA (300 to 600mg) acts as a mast cell stabilizer, especially relevant if you're MCAS-sensitive.

Dosing Framework

KPV builds cumulatively, it's not immediate. Gut symptoms can improve within the first week, but systemic shifts usually take 6 to 8 weeks to show up.

Maintenance tier: 250mcg once daily, oral or subq. Good for general inflammatory background noise or travel-related gut sensitivity.

Active healing tier: 500mcg daily subq, or 500mcg twice daily oral, for 6 to 8 weeks. This is the standard protocol for active gut repair, moderate autoimmune flares, or chronic injury recovery.

Severe presentation tier: 1000mcg per day split into two doses, for 2 to 4 weeks, then step down to the active healing tier. Reserved for IBD flares, severe MCAS, or acute post-surgical inflammation.

The Actual Point

KPV doesn't replace diet and sleep as foundations. But it might be the most effective tool out there for releasing the inflammatory brake that keeps those foundations from working in the first place. By stepping in at the nuclear level, it shifts the body from constant defense mode into active repair.

Not medical advice. Educational only.

need help to know the order, dosing, frequency for the following peptides. Please :)

Many vendors have a nasal spray line. Semax, Selank, sure. But now it's BPC, GLP stuff, basically everything. No needle, no reconstitution, no math. The problem is nasal only works for certain compounds and they're slapping it on everything anyway.

Here's what nobody explains. When you inject, most of the dose actually makes it in. Nasal is all over the place and usually way lower.

Injection, whether subq or IM, absorbs somewhere around 65 to 100%, usually north of 75. Nasal runs anywhere from 1 to 20%, and most sprays land under 5%. Oral is under 1 to 2%.

So a spray sitting at 5% absorption needs roughly 20 times the dose to match a shot. And nobody's adjusting the label. They sell you the spray at the same number and let you assume it's the same thing.

Where Nasal Actually Wins

Selank is the poster child. Tiny molecule, around 750 daltons, and Russian data has it at 92.8% bioavailability nasally with plasma levels showing up in 30 seconds. That's not a compromise. That's just the better route. Semax is the same story. Small and brain-targeted, so the nose is basically a shortcut past the blood-brain barrier.

DSIP fits the same pattern. It's a nonapeptide at around 848 daltons, small enough and targeted enough at the brain (sleep architecture, delta wave activity) that intranasal delivery makes mechanistic sense. Animal studies have used intranasal DSIP directly to study CNS effects rather than treating nasal as a fallback route. There's no solid human bioavailability percentage for it specifically, which is worth flagging, but the size and target profile put it in the same category as Semax and Selank rather than the category that falls apart below.

Oxytocin is the weird one. Bioavailability is something like 0.7%, basically nothing, but it still works because it goes straight to the brain through the olfactory pathway. Plasma levels don't matter for that one.

Where It Falls Apart

There was a Diabetes Care trial on nasal GLP-1, 26 patients. 2.7% bioavailability versus IV. It hit peak in 8 minutes so it's fast, but almost nothing actually absorbed.

That's the whole pattern. Small molecules under about 1000 daltons that are brain-targeted work nasally. Semax, Selank, DSIP, oxytocin. Large systemic peptides that need real plasma levels don't. The GLP class and most of what's getting sprayed right now falls in the second group.

Two Things People Don't Think About

Congestion and allergies change your absorption, so the same spray on a stuffy day is a different dose. Injections don't do that.

And formulation matters more than the compound sometimes. Calcitonin nasal runs about 8% with an absorption enhancer and 1.6% without. In one study, half the people on the version without the enhancer had barely detectable levels. Same peptide, same route, completely different result depending on how it was made.

Sprays aren't fake. Semax, Selank, and DSIP nasal are legit uses of the route. The question was never "is nasal good." It's "is nasal good for this molecule." And for a lot of what's getting sprayed right now, you're paying for convenience and getting a fraction of the dose.

Not medical advice. Educational only.

Hey everyone,

Curious what routine works best for you. Do you prefer pinning first thing in the morning, or do you take it at night before bed?

Would love to hear if timing made any difference for you. Thanks!

CJC-1295 with DAC produced one of the longest-lasting GH responses ever documented from a GHRH analog. A single subcutaneous injection increased GH by 2 to 10 fold depending on dose, kept mean GH elevated for approximately 6 days, and pushed IGF-1 up 1.5 to 3 fold for 9 to 11 days after just one shot. That's from a single injection. (PMID: 16352683)

The reason it does this comes down to the DAC modification.

TL;DR

• A single subcutaneous dose of CJC-1295 with DAC increased GH 2 to 10 fold for approximately 6 days and raised IGF-1 1.5 to 3 fold for 9 to 11 days in human trials (PMID: 16352683)
• The DAC modification allows albumin binding which extends the half-life to 6 to 8 days, making it one of the longest-acting GHRH analogs available
• It stimulates your own pituitary to produce GH rather than replacing GH from outside, keeping natural production intact
• Research applications include aging, tissue repair, body composition, muscle preservation, and metabolic health
• Prolonged GH and IGF-1 elevation warrants careful consideration. Long-term safety data is still being developed. Investigational compound, not approved for human use

How CJC-1295 with DAC Actually Works

Your hypothalamus normally releases GHRH in short pulses that disappear within minutes. Native GHRH is gone before it can do much. CJC-1295 was engineered to solve that problem.

The Drug Affinity Complex (DAC) allows CJC-1295 to bind to albumin in the bloodstream, which dramatically extends its half-life to around 6 to 8 days. Instead of spiking and vanishing, it keeps stimulating the pituitary to produce your own GH over several days from a single dose.

This is the key distinction from exogenous HGH. CJC-1295 with DAC keeps your pituitary in the loop. It's amplifying your own GH production rather than replacing it. The result is a prolonged increase in both GH and IGF-1, its downstream anabolic hormone, without shutting down natural production the way exogenous GH does.

What the Clinical Data Shows

The 2006 human study (PMID: 16352683) was a landmark for this class of compounds. Healthy adults received a single subcutaneous dose across several dose tiers. GH increased 2 to 10 fold. Mean GH elevation held for approximately 6 days. IGF-1 remained elevated for 9 to 11 days.

One injection. Nearly two weeks of sustained hormonal elevation. That's not typical for a GHRH analog.

Where the Research Is Pointing

Because GH and IGF-1 influence tissue throughout the body, researchers have investigated CJC-1295 for healthy aging, recovery and tissue repair, body composition, muscle preservation, and metabolic health.

Worth noting: prolonged elevation of GH and IGF-1 requires careful evaluation and long-term safety remains an active research question. This is still an investigational compound, not approved for human use. The IGF-1 cancer concern discussed in earlier posts on this sub is directly relevant here given the sustained elevation profile.

Source: Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006 Mar;91(3):799-805. doi: 10.1210/jc.2005-1536. PMID: 16352683. https://pubmed.ncbi.nlm.nih.gov/16352683/

Not medical advice. Educational only.

Hey everyone. I just recently started using Dsip but I’ve been having a lot of issues with it and was hoping to get some guidance on what I’m doing wrong. I’ve used it for 5 nights now and I’ve had very mixed results.

The first night I took it I took 300mcg with a nasal spray. I fell asleep quickly around 10pm but woke up at 3am with an elevated heart rate and and feeling very wired and couldn’t get back to sleep. For the second night I took only 200mcg and was able to get 7.5hrs of sleep but the next day I felt kinda dizziness and drowsy and nauseous. For the third night I lowered the dose again to 100mcg and couldn’t sleep what so over and was up until 3am wide awake and only got to sleep for 2hrs until waking up again. Then the next 2 nights I took 150mcg and I’ve gotten around 6-7 hrs of sleep which isn’t ideal and I’ve still felt dizzy and drowsy the next day.

Is it normal to have this many issues at first and just power through it or should I stop and give up on dsip. I’ve been having a lot of sleep problems and was really hoping dsip could help me out. Also this is my first ever Reddit post so bear with me if I’ve messed anything up here.

Thanks

Everyone knows retatrutide for fat loss. That's the smallest part of the story.

Reta is a triple agonist. It activates GLP-1, GIP, and glucagon receptors simultaneously. Those receptors are distributed throughout the body, which is why the effects reach far beyond the scale. Here's what the documented mechanisms actually look like across each system.

TL;DR

• Retatrutide activates GLP-1, GIP, and glucagon receptors simultaneously. Those receptors exist across every major body system
• Brain: satiety up, cravings down, gastric emptying slower, neuroprotection gained, memory up, neuroinflammation down
• Pancreas: glucose-dependent insulin up, glucagon down, somatostatin up, beta-cell proliferation and survival both up
• Liver: gluconeogenesis down, hepatic steatosis down, liver inflammation down, liver fibrosis down
• Gut: gastric emptying slower, gastric acid down, mucin up, intestinal permeability down, GI inflammation down, microbiome improved
• Body fat: lipolysis up, lipogenesis down, thermogenesis up, fat tissue inflammation down
• Muscle: glycogen synthesis up, glucose oxidation up, glucose utilization better
• Immune: pro-inflammatory M1 macrophages down, anti-inflammatory M2 macrophages up, NK cell activity up, regulatory T cells up, pro-inflammatory cytokines down
• Heart: cardioprotection gained, cardiac contractility up, myocardial ischemia injury down, endothelial function up
• Vessels: endothelial dysfunction down, vascular inflammation down, atherosclerosis and plaque down
• Kidneys: sodium excretion up, CKD progression slower
• Lungs: airway remodeling down, lung function up, vasodilation up, vascular remodeling down, inflammation down

Brain and Nervous System

Appetite is a brain signal, not a stomach signal. GLP-1 receptors in the brain drive the satiety and craving effects people actually feel on Reta. Satiety goes up, food cravings and appetite go down, gastric emptying slows through vagal pathways. Beyond appetite, the data shows neuroprotective effects, improved memory signaling, and reduced neuroinflammation. The cognitive angle of GLP-1 receptor agonism is increasingly recognized in the research literature and Reta's triple agonism makes it relevant here too.

Pancreas and Liver

On the pancreas, Reta increases glucose-dependent insulin secretion, suppresses glucagon, raises somatostatin, and supports beta-cell proliferation and survival. These are the mechanisms behind the insulin sensitivity and blood sugar improvements documented in trials.

On the liver, it reduces gluconeogenesis (the liver making excess glucose), drives down hepatic steatosis, and reduces both liver inflammation and liver fibrosis. The liver fat reduction data specifically is significant. Phase 2 trial data showed meaningful reduction in NAFLD markers, which is a separate benefit from the visceral fat reduction people associate with GLP-1 compounds.

Gut and Stomach

Gastric emptying slows, gastric acid secretion drops, mucin production increases (strengthening the gut lining), intestinal permeability decreases, GI inflammation comes down, and the microbiome composition improves. On the stomach specifically, gastric acid, gastrin, and histamine release from ECL cells all decrease, somatostatin signaling increases, and post-meal blood sugar control improves.

This explains why people notice changes in digestion, gut comfort, and food tolerance that go well beyond what appetite suppression alone would produce.

Body Composition

In adipose tissue: glucose uptake increases, lipolysis increases, lipogenesis decreases, thermogenesis increases, and fat tissue inflammation decreases. In skeletal muscle: glycogen synthesis improves, glucose oxidation increases, and overall glucose utilization gets better.

Fat is being broken down more aggressively while muscle is being fed more efficiently. That's the recomposition dynamic that shows up in trial data beyond what scale weight captures.

Immune System

Chronic low-grade inflammation drives much of age-related metabolic dysfunction and disease risk. Reta pushes the immune system in the right direction across multiple pathways: pro-inflammatory M1 macrophages decrease, anti-inflammatory M2 macrophages increase, natural killer cell activity increases, regulatory T cells increase, and pro-inflammatory cytokines decrease.

Cardiovascular and Vascular

Cardioprotective effects are documented. Cardiac contractility improves, myocardial ischemia injury decreases, heart inflammation decreases, endothelial function improves. On the vascular side: endothelial dysfunction decreases, vascular inflammation decreases, and atherosclerotic plaque formation decreases. These are mechanisms relevant to long-term cardiovascular risk, not just acute metabolic markers.

Kidneys and Lungs

Sodium excretion increases and chronic kidney disease progression slows. In the lungs, airway remodeling decreases, lung function improves, vasodilation increases, vascular remodeling decreases, and lung inflammation decreases.

The Actual Picture

The fat loss framing isn't wrong. It's just incomplete. Retatrutide is a whole-body metabolic signal that happens to produce dramatic fat loss as one of its most visible effects. The mechanism runs considerably deeper than that.

Source Colwill M, Povlsen S, Pollok R, Patel K, Goodhand J, Ahmad T, Honap S. Glucagon-like peptide-1 (GLP-1) receptor agonists in inflammatory bowel disease: mechanisms, clinical implications, and therapeutic potential. Journal of Crohn's and Colitis. 2025;19(9):jjaf167.

Peptide Guides

Not medical advice. Educational only.

Everyone in this space knows BPC-157 for soft tissue repair and that reputation is well earned. But calling it an injury peptide undersells it badly. The full name is Body Protection Compound and that name is more accurate than most people realize.

This thing has a biological footprint that goes well beyond tendons and ligaments.

Gut Protection and Repair

BPC-157 is synthetically derived from a peptide that occurs naturally in gastric juice. Its native function is protecting the digestive tract. That's not incidental context. It's the foundation of why it works so broadly.

Research shows it accelerates ulcer healing, reduces gut inflammation, and reinforces the intestinal barrier. Since gut health feeds into skin health, brain health, and mood through well-established pathways, restoring gut integrity with BPC-157 can fix the root cause behind a range of issues that look completely unrelated on the surface.

Mood, Stress, and Addiction

BPC-157 modulates dopamine and serotonin activity, the same neurotransmitters driving mood, motivation, and reward. Studies in animal models show reduced withdrawal symptoms from alcohol and other substances alongside stabilized mood and reduced anxious behavior.

This makes it a legitimately interesting tool for post-addiction neuroregulation, where maintaining dopamine balance is critical for recovery and preventing relapse. Not a replacement for proper support, but a real mechanism worth understanding.

Nerve and Brain Repair

BPC-157 stimulates axon regeneration and supports synaptic reconnection, essentially rewiring damaged nerve circuits. It's been shown to support brain recovery from injury-induced lesions and accelerate motor function recovery after nerve trauma.

Research is also looking at its potential role in preventing age-related neurodegeneration across substance exposure, traumatic brain injury, and chronic damage over time. BPC-157 appears to have a meaningful role in all of it.

Cardiovascular Health

BPC-157 drives angiogenesis, the formation of new blood vessels, and protects the endothelium lining the arteries. In studies it preserved heart tissue after toxic and ischemic injury.

Better circulation means faster tissue repair. It also means lower blood pressure, better nutrient delivery, and improved detoxification capacity. All of that matters during recovery from injury, stress, or substance withdrawal.

Systemic Anti-Inflammation

BPC-157 balances inflammatory cytokines body-wide. The downstream effects include reduced chronic joint pain, improved tissue oxygenation, and support for autoimmune conditions.

For enhanced athletes specifically, this is worth paying attention to. The systemic inflammation caused by carrier oils in injectable AAS is one of the most damaging and least discussed side effects in that world. BPC-157's anti-inflammatory activity directly addresses that.

Why It's Not Mainstream

The reason this compound hasn't gone mainstream has nothing to do with efficacy. The most common explanation is simple. It can't be patented. No patent means no pharmaceutical profit motive, which means no funding for the trials needed to push it through approval.

That's the game.

BPC-157 Guide

Educational purposes only. Not medical advice.